Tibet Weixinkang Medicine Co., Ltd. (SHA:603676)
China
· Delayed Price · Currency is CNY 10.60
0.00 (0.00%)
Apr 30, 2026, 3:00 PM CST
Tibet Weixinkang Medicine Revenue
Tibet Weixinkang Medicine had revenue of 322.14M CNY in the quarter ending March 31, 2026, with 8.90% growth. This brings the company's revenue in the last twelve months to 1.16B, down -9.08% year-over-year. In the year 2025, Tibet Weixinkang Medicine had annual revenue of 1.14B, down -12.65%.
Revenue (ttm)
1.16B
Revenue Growth
-9.08%
P/S Ratio
3.94
Revenue / Employee
1.69M
Employees
689
Market Cap
4.58B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.14B | -164.48M | -12.65% |
| Dec 31, 2024 | 1.30B | -22.41M | -1.69% |
| Dec 31, 2023 | 1.32B | -75.89M | -5.43% |
| Dec 31, 2022 | 1.40B | 364.92M | 35.31% |
| Dec 31, 2021 | 1.03B | 317.96M | 44.43% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jinling Pharmaceutical Company | 3.16B |
| Zhuhai Rundu Pharmaceutical | 1.19B |
| Wuhan Hiteck Biological Pharma Co.,Ltd | 543.82M |
| Guizhou Sanli Pharmaceutical Co.,Ltd | 1.68B |
| Newland Pharmaceutical | 659.54M |
| Jinhe Biotechnology CO., LTD. | 2.88B |
| Shandong Sinobioway Biomedicine | 274.81M |
| Hubei Biocause Heilen Pharmaceutical | 459.02M |